基因组分类器用于新诊断前列腺癌的治疗选择
该系统综述检索了2010至2018年PubMed、Embase、Cochrane Central及美国泌尿外科学会会议摘要,最终纳入21篇全文文献,包括Prolaris 8项、Oncotype Dx 8项和Decipher 5项研究。作者认为,基于前列腺活检生物标志物的基因组检测结果可与临床病理变量联合使用,以提高对新诊断前列腺癌患者的风险分层能力,但仍需更多关于长期患者结局和成本效果的数据。
要点
- 纳入21篇全文文献,Prolaris 8项、Oncotype Dx 8项、Decipher 5项。
- 基因组检测结果可与临床病理变量联合用于新诊断前列腺癌的风险分层。
- 仍需更多关于这些检测对长期患者结局影响及成本效果的数据。
核心结论
- 基于前列腺活检生物标志物的基因组检测结果可与临床病理变量联合使用,以提高对新诊断前列腺癌患者的风险分层能力。
- 仍需更多关于这些检测对长期患者结局影响及成本效果的数据。
研究设计与样本
- 系统综述,检索PubMed、Embase、Cochrane Central及美国泌尿外科学会会议摘要,发表时间2010至2018年。
- 由两位作者评估Prolaris、Oncotype Dx和Decipher检测研究的纳入资格。
- 排除结果来自手术标本而非活检标本的研究。
- 因方法学、定义和结局指标存在显著差异,未进行Meta分析。
- 初检检索到729篇文献,去除重复270篇并排除不相关432篇后,21篇全文文献纳入分析。
主要发现
- 纳入的21篇全文文献包括Prolaris 8项研究、Oncotype Dx 8项研究和Decipher 5项研究。
- 对每种基因组检测提取了不良病理、生化复发、转移和前列腺癌特异性死亡风险相关数据。
临床怎么用
- 作者认为,基于前列腺活检生物标志物的基因组检测结果可与临床病理变量联合使用,以提高对新诊断前列腺癌患者的风险分层能力。
- 作者指出,仍需更多关于这些检测对长期患者结局影响及成本效果的数据。
局限性
- 因方法学、定义和结局指标存在显著差异,未进行Meta分析。
- 仍需更多关于这些检测对长期患者结局影响及成本效果的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review systematically the literature on genomic tests for prostate cancer (PCa) and to evaluate the current state of the evidence on their use in patients with newly diagnosed PCa. METHODS: We conducted a systematic review by searching PubMed, Embase, Cochrane Central and conference abstracts from the American Urological Association, published between 2010 and 2018. Studies evaluating Prolaris, Oncotype Dx and Decipher assays were assessed for inclusion by two authors. Studies were excluded if the results were derived from surgical specimens rather than biopsy specimens. A meta-analysis was not performed owing to significant variations in methodologies, definitions and outcome measures. RESULTS: A total of 729 articles were retrieved in our initial search. After removing duplicates (270) and excluding articles deemed not relevant (432), 21 full-text articles were deemed suitable for inclusion in the present analysis. The full-text articles comprised eight studies on Prolaris, eight studies on Oncotype Dx and five studies on Decipher. For each genomic test we extracted data regarding the risks of adverse pathology, biochemical recurrence, metastasis and PCa-specific mortality. CONCLUSION: The results of genomic tests that use biomarkers derived from prostate biopsy can be used in conjunction with clinicopathological variables to improve our ability to risk-stratify patients with newly diagnosed PCa. Additional data are needed on the impact of using these tests on long-term patient outcomes and their cost-effectiveness.
引用
- Fine ND, LaPolla F, Epstein M, et al. Genomic classifiers for treatment selection in newly diagnosed prostate cancer. BJU Int. 2019. PMID: 31055874. doi:10.1111/bju.14799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。